Seeking Alpha

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study ...
Nasdaq

Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder (FSAD) ...
Nasdaq

Lexaria Bioscience’s Phase 1b study starts patient dosing, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience (LEXX) shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient ...
Seeking Alpha

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT will include presentations by Daré management and key opinion leaders in sexual medicine SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré ...
Becker's ASC

Exalenz Bioscience, Acute Liver Failure Study Group to study use of breath test for acute liver failure: 5 points

Exalenz Bioscience is collaborating with the Acute Liver Failure Study Group. 1. Exalenz Bioscience and the Acute Liver Failure Study Group will study the ability of the BreathID Methacetin Breath ...
Business Insider

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women. SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Daré ...
Hosted on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...
Business Insider

Lexaria Bioscience begins dosing for GLP-1 study #4

Lexaria Bioscience (LEXX) has begun dosing in the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4. The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology ...
Business Wire

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived ...
Business Wire

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ...